Board summary
Key figures
34,205
Registered population
61.6% aged 18–64
19.2%
Aged 65+
ICB 20.0% · England 17.9%
6.3%
Ethnic minority (non-White)
4.3% Asian · England 9.6%
41.1%
In IMD quintile 1
ICB 30.6% · England 21.0%
~14,496
Core20 residents (est.)
Resident basis; registered basis ~13,645 · see page 3
6,491
Hypertension register
+3.85% in 3 yrs · England +5.60%
409
SMI register
16.4% of Blackburn with Darwen (LAD)'s
843
COPD register
Reviews -2.13% in 3 yrs
Forecast to 2030
7,096
Hypertension patients, 2030
+605 on today
66.7%
QRISK ≥20% on statins, 2030
+3.81pp over 3 yrs
5.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Annual asthma reviews trail national rates.
Annual asthma reviews cover 62.5% of the 2,664 register (England 65.7%, -2.8% over three years), leaving about 1,000 unreviewed patients.
MMR coverage drops by second dose.
At age 5, MMR coverage drops by 14.2 pp between dose 1 (95.2%) and dose 2 (81.0%, England 82.8%), suggesting a recall gap.
Breast and cervical screening exceed benchmarks.
Breast screening rose +29.1% over three years to 73.8% (England 69.9%), alongside 74.7% cervical screening in women aged 25-49 (England 66.8%).
Population, age and ethnicity
Older patients reach 19.2% of the registered list, exceeding the borough's 13.5%
Across three practices serving 34,205 registered patients, 19.2% (6,555) are aged 65+, higher than Blackburn with Darwen (LAD) (13.5%), below the ICB (20.0%), and above England (17.9%). Children aged 0–17 make up 19.2% (6,577), below the borough (24.0%), ICB (19.6%), and England (19.6%). In associated Census areas, 93.7% of residents are White (LAD 60.4%, ICB 87.8%, England 81.1%) and 4.3% Asian or Asian British (LAD 35.7%, ICB 9.4%, England 9.6%). Age figures reflect registered patients, whereas ethnicity captures Census residents and may differ from practice lists.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Blackburn with Darwen (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Blackburn with Darwen LA) | 1,724 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 87.7% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 57.3% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Blackburn with Darwen LA) | 951 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Blackburn with Darwen LA) | 16.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation affects 41.1% of patients and spans 31.0 percentage points across practices
Core20 deprivation covers 41.1% of registered patients (about 14,500 estimated residents), exceeding England (21.0%) and the ICB (30.6%), though below Blackburn with Darwen (LAD) (59.6%). Practice concentration spans 31.0 percentage points, from Darwen Healthlink (45.5%, estimated 6,886 patients) and Darwen Healthcare (41.4%, estimated 6,147 patients) to Spring-fenisco Healthlink (14.5%, estimated 612 patients). The weighted practice share of 39.9% reveals a 1.19 percentage point discrepancy against the PCN rate.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
409
SMI register
1.22% recorded prevalence
162
Learning disability register
0.48% recorded prevalence
8
Care homes, 249 beds
In the PCN catchment
9.9%
Provide unpaid care
Blackburn with Darwen (LAD), Census 2021
Severe mental illness prevalence is 1.2% (409 patients), below Blackburn with Darwen (LAD) (1.3%), matching the ICB (1.2%), and above England (1.0%). Learning disability prevalence is 0.5% (162 patients), below the borough, ICB and England (all 0.6%). Eight care homes in the PCN catchment provide 249 beds.
Severe mental illness: physical health checks
On an SMI register of 409 patients (1.2% prevalence), 12-month blood pressure recording is 74.7% (England 83.4%) and BMI recording is 75.0% (England 82.1%). Physical check coverage lags comparators across both measures.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,491
Hypertension register
+3.85%
Register growth, 3 yrs
Blackburn with Darwen (LAD) +4.97% · England +5.60%
+1.80pp
BP control, under 80
≤140/90 · +1.75pp aged 80+
+605
More patients by 2030
Forecast 7,096 (20.82%)
Hypertension case-finding and control
Hypertension register prevalence is 19.3% (6,491 patients), higher than in Blackburn with Darwen (LAD) (15.0%), the ICB (17.2%) and England (15.2%). However, recent blood pressure recording is 85.9%, trailing the borough (88.1%), ICB (89.0%) and England (90.0%), after falling 2.2% over three years (England +3.6%). Overall treatment to target is 66.2% (England 70.3%), and under-80s blood pressure control is 65.1% (England 67.8%), ranging from 63.9% at Darwen Healthcare and 65.3% at Darwen Healthlink to 68.9% at Spring-fenisco Healthlink, while over-80s control reaches 83.5% (England 81.2%). Hypertension control in patients aged under 80 lags national benchmarks, indicating an opportunity to prioritise routine blood pressure review and recall across practices.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy stand at 58.2%, below England (63.6%) despite a +7.0% three-year change (England +6.2%). CKD lipid coverage is 65.6% (England 70.3%). Lower coverage across both cohorts indicates an opportunity to review lipid-lowering therapy initiation.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 69,002 | £1.50 | £1.64 | £1.86 | £103,503 |
| Cardiovascular (all), 2025 | 106,959 | £3.13 | £3.38 | £3.33 | £334,782 |
For lipid-modifying drugs in 2026, the PCN prescribed 69,002 items at £1.50 per item (spend £103,503), below Blackburn with Darwen (LAD) (£1.83), the ICB (£1.64) and England (£1.86), spending £24,841 less than at England's unit cost. Prescribing cost per item is lower than comparators, though unit cost does not establish prescribing efficiency or treatment appropriateness.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−2.75%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.23%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 8.4% (2,664 patients vs 6.6% in England), with paediatric prescribing reaching 2,741 items per 1,000 aged 5–19 (England 1,488). However, annual asthma reviews fell 2.8% over three years (England +4.4%) to 62.5% (England 65.7%), leaving an estimated gap of about 1,000 unreviewed patients. In contrast, COPD reviews reached 79.8% (England 76.4%) across 843 patients (2.5% prevalence vs 1.9% England). High prescribing alongside trailing reviews may indicate unmet review need among paediatric asthma patients.
Cancer register and children's immunisation
Cancer prevalence is 4.2% (1,422 patients vs 3.8% England). In childhood immunisations, 12-month 6-in-1 coverage is 79.2%, 15.8 pp below the 95.0% target. Furthermore, age-5 MMR coverage drops 14.2 pp from dose 1 (95.2%) to dose 2 (81.0%), widening to a 20.5 pp difference at Darwen Healthlink. Drop-off before pre-school boosters suggests second-dose recall is a key operational priority.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
In 2022 across NHS Lancashire and South Cumbria ICB, 52.4% of cancers with a known stage were diagnosed at stage 1 or 2 (4,642 of 8,863 staged cases), trailing England (55.3%) and 22.6 pp below the 75.0% national ambition. Known-stage completeness was 74.6% (8,863 of 11,883 cancers). ICB early diagnosis fell 1.2 pp from 2013 to 2022, requiring about 2,010 extra early diagnoses annually to meet the ambition, with low early detection in lung (31.1%) and bowel (44.2%). Darwen PCN cancer prevalence grew +8.9% over three years (England +9.0%, ICB +9.3%). System staging data reflects regional pathways rather than PCN performance.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, East Lancashire Hospitals NHS Trust achieved 73.2% on cancer 62-day treatment, 11.8 pp below the 85.0% standard, while Bolton NHS Foundation Trust achieved 69.7%, Lancashire Teaching Hospitals NHS Foundation Trust 75.0%, the ICB 73.6%, and England 71.2%. East Lancashire met the 28-day faster diagnosis standard at 81.5% (standard 75.0%), against Bolton (80.5%), Lancashire Teaching Hospitals (82.9%), the ICB (78.4%), and England (79.3%). For diagnostics, 3.2% waited 6+ weeks at East Lancashire (England 23.1%), though cystoscopy reached 32.7%. These provider figures reflect acute pathway pressures rather than PCN performance.
| Pathways within standard (%) | East Lancashire | Lancashire | Bolton | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.50 | 82.90 | 80.48 | 78.39 | 79.32 |
| 31-day treatment (96%) | 98.11 | 89.43 | 96.50 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 73.16 | 75.04 | 69.66 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Lancashire | Lancashire | Bolton | England |
|---|---|---|---|---|
| MRI | 0.43 | 2.41 | 2.05 | 21.40 |
| CT | 0.15 | 14.97 | 19.40 | 9.92 |
| Echocardiography | 0.00 | 13.85 | 3.48 | 28.48 |
| Colonoscopy | 0.95 | 0.00 | 1.33 | 30.83 |
| Gastroscopy | 1.16 | 0.00 | 2.06 | 29.02 |
| All 15 DM01 tests | 3.25 | 26.65 | 15.78 | 23.14 |
| Community services activity | Blackburn With Darwen residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 535 | 193,720 |
| Referrals | 230 | 29,855 |
| Patients with a contact | 305 | 65,335 |
Community services (residents of Blackburn With Darwen), Jun 2026 (provisional). In June 2026, provisional community services data recorded 455 care activities for Blackburn With Darwen residents, within 533,345 activities across NHS Lancashire and South Cumbria Integrated Care Board. Borough residents aged 65 and over accounted for 36.4% of contacts (195 of 535). These experimental figures reflect submitting providers and resident activity rather than unique PCN registered patients.
Practice variation and patient experience
Practice variation and patient experience
Across 2025/26 QOF, clinical-domain points reached 99.6% to 100.0% across all three practices. However, vaccination and immunisation achievement spanned 59.2 pp, ranging from 34.1% at Darwen Healthlink and 39.2% at Spring-fenisco Healthlink to 93.3% at Darwen Healthcare. Personalised care adjustments in this domain remained between 2.9% and 4.9%, showing wide delivery contrasts rather than recorded exclusions.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Darwen Healthcare | 124 | 41.4 | 81.6% | 74.2% | 89.1% |
| Spring-fenisco | 114 | 14.5 | 87.5% | 80.0% | 87.0% |
| Darwen Healthlink | 94 | 45.5 | 58.0% | 72.0% | 79.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Nineteen of 25 tracked measures trail England trends, led by heart failure reviews
Across 25 tracked measures, 19 trail national three-year trends. The widest relative lags occur in chronic disease management: annual heart failure reviews fell 11.6% (England +8.7%), asthma reviews fell 2.8% (England +4.4%), and hypertension blood pressure checks fell 2.2% (England +3.6%). SMI blood pressure checks fell 0.6 pp (England +4.4 pp). Conversely, strengths outpace England in preventative care: breast screening rose 29.1% (England +8.4%), diabetes statin prescribing increased 5.3% (England +2.1%), and learning disability QOF prevalence rose 19.4% (England +5.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Asthma reviews
Dementia register
Hypertension BP reading
BP check (SMI)
Breast screening (53-70)
Diabetes statin (no CVD)
Cervical screening
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Blackburn with Darwen (LAD) | Asset | PCN | Blackburn with Darwen (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 8 (249 beds) | n/a | Schools (catchment) | 42 | n/a |
| Children's centres | 2 | 13 | Places of worship | 26 | 99 |
| Libraries | 3 | 6 | Primary schools (LA maintained) | 13 | 45 |
| Primary academies | 2 | 6 | Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review recall
Annual asthma reviews stand at 62.5% (England 65.7%, ICB 65.0%, LAD 63.5%) after falling 2.8% over 3 years (England +4.4%) on a 2,664-patient register (8.4% prevalence), leaving about 1,000 unreviewed patients. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Pre-school MMR second-dose catch-up
At age 5 (cohort 84), MMR drops 14.2 pp from dose 1 (95.2%) to dose 2 (81.0%, ICB 87.4%, England 82.8%), and 20.5 pp at Darwen Healthlink (93.2% to 72.7%). For discussion: practices could audit children due for second-dose MMR and test flexible catch-up reminders before school entry. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Learning disability register validation
Learning disability register prevalence is 0.5% (162 patients vs 0.6% in LAD, ICB and England; +19.4% 3-year change vs England +5.4%), giving a modelled gap of 39 to 51 patients across 34,205 patients. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension review and recall protocol (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall catch-up (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Urgent referral protocol review (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Option 1 · Structured asthma review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Pre-school MMR second-dose catch-up (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · QOF vaccination and immunisation-domain achievement | 10YHP sickness to prevention · 95% target | PCN & Practice |
| Option 3 · Learning disability register validation (p12) | Registered population · Learning disability register · Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
